Hives clinical trials at UCLA
3 research studies open to eligible people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
open to eligible people ages 18 years and up
This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).
Los Angeles 5368361, California 5332921 and other locations
Barzolvolimab in Participants With Chronic Spontaneous Urticaria
open to eligible people ages 18 years and up
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Los Angeles 5368361, California 5332921 and other locations
Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
open to eligible people ages 18 years and up
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for Hives research studies include Gary J. Schiller, MD April W. Armstrong, MD, MPH.
Last updated: